BioPharma Resources

Drug Trial Radar · NCT03179904

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

MC1633 Phase II Trial to Evaluate the Efficacy of the FASN Inhibitor, TVB-2640, in Combination With Trastuzumab Plus Paclitaxel or Endocrine Therapy in Patients With HER2+ Metastatic Breast Cancer Resistant to Trastuzumab-Based Therapy

Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

17

Actual

Start

Aug 3, 2017

Primary completion

Jul 30, 2024

Study completion Mar 13, 2026

Sponsor

Lead sponsor
Mayo ClinicAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 7, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial studies how well FASN inhibitor TVB-2640, paclitaxel, and trastuzumab work in treating patients with HER2 positive breast cancer that has spread to other places in the body (metastatic). FASN inhibitor TVB-2640 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Trastuzumab is a form of targeted therapy because it attaches itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the body's immune system. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Estrogen can cause the growth of breast cancer cells. Drugs used in endocrine therapy either lower the amount of estrogen made by the body or blocks the use of estrogen by the tumor cells. This may help stop the growth of tumor cells that need estrogen to grow. Giving FASN inhibitor TVB-2640 and trastuzumab in combination with paclitaxel or endocrine therapy may help control the disease in patients with HER2 positive breast cancer.

Conditions

  • Advanced Breast Carcinoma
  • HER2-Positive Breast Carcinoma
  • Anatomic Stage III Breast Cancer AJCC v8
  • Anatomic Stage IV Breast Cancer AJCC v8
  • HER2-positive Breast Cancer

Interventions

  • AnastrozoleDrug

    Given PO

  • DenifanstatDrug

    Given PO

  • ExemestaneDrug

    Given PO

  • FulvestrantDrug

    Given IM

  • EchocardiographyProcedure

    Undergo ECHO

  • LetrozoleDrug

    Given PO

  • PaclitaxelDrug

    Given IV

  • TrastuzumabBiological

    Given IV

  • Computed TomographyProcedure

    Undergo CT

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • BiopsyProcedure

    Undergo biopsy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response RateTime frame: 14 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic in Arizona

    Scottsdale, Arizona

  • Mayo Clinic in Florida

    Jacksonville, Florida

  • Mayo Clinic in Rochester

    Rochester, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.